Horizon Pharma plc announces FDA approval to expand the indication for Procysbi (cysteamine bitartrate) delayed-release capsules to include children one year of age and older living with nephropathic cystinosis. The U.S. Food and Drug Administration (FDA) has approved an expansion to the indication for Horizon Pharma plc’s Procysbi (cysteamine bitartrate) delayed-release capsules to include children one year…